Resources · Implementation guide
An engagement,
phase by phase.
No phase is skipped and no phase is padded. Each one exists to produce a named artifact that the next phase — and the eventual go/no-go decision — depends on.
Phase 1 · Discover
Understand the workflow as it actually runs.
We map the current between-session process end to end: who touches it, where it breaks, what systems it crosses, and what it costs the team today. No product configuration happens in this phase.
Produced
A written workflow map the partner corrects and approves.
Also established
Population boundary, EHR context, coverage policy, and the buying path.
Phase 2 · Design
Write down who owns what before anything runs.
Together we draft the responsibility model, the bounded use case, the evidence plan (what will be measured, including burden), and the stop rules — the conditions under which the engagement narrows or ends.
Produced
Responsibility model · evidence plan · stop rules, all named and signed.
Also completed
Security, privacy, and clinical diligence begin against the trust center.
Phase 3 · Validate
Prove it with synthetic data first.
Configuration, roles, consent flows, review paths, failure paths, and rollback are exercised with synthetic patients and records. Real patient data is not used in this phase, anywhere, for any reason.
Produced
A synthetic acceptance record: what was tested, what passed, what remains open.
Also verified
Support routes, escalation handoffs per the partner’s own policy, and deactivation.
Phase 4 · Decide
An explicit decision, not a drift into production.
With the artifacts in hand, the partner and Peacefull make a bounded go/no-go decision: activate a named cohort under named approvals, narrow the scope, defer, or stop. Any real-patient activation is deliberate, reversible, and evidence-reviewed on a set cadence.
What we ask of a partner
Real commitment, honestly stated.
Named owners
An executive sponsor, a clinical champion, and an operational owner.
Workflow access
Time with the people who actually run the between-session process.
Decision cadence
Timely reviews at each phase boundary.
Candor
Adoption, burden, and failure reported as observed — both directions.
Start Phase 1
Bring us the workflow, not a patient.
Email the organization name, your role, approximate clinician count, and the between-session process you want to improve. Do not include PHI.
Start the conversation Do not include patient information or clinical details in email.